GNLX:NASDAQ
Genelux Corp
$2.88
arrow_upward
+5.49%(+0.15) 1D
$2.90
arrow_upward
+0.69% (+0.020)bedtimeAfter hours
Closed: Aug 27, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.72
High
$2.95
Low
$2.72
Mkt. cap
130.31M
Avg. vol.
287.99K
Volume
594.42K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.60
Shares outstanding
45.24M
No. of employees
26
Open
$2.72
High
$2.95
Low
$2.72
Mkt. cap
130.31M
Avg. vol.
287.99K
Volume
594.42K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.60
Shares outstanding
45.24M
No. of employees
26
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com
AI content may include mistakes. Learn more